Shawn Leland, Fore Biotherapeutics interim CEO
August 23, 2023 10:30 AM EDT
Financing
Startups

Fore scores $75M Se­ries D, tees up new lead­er­ship with ex-El­e­va­tion CEO Shawn Le­land at the helm — for now

Kyle LaHucik

Senior Reporter

Fore Bio­ther­a­peu­tics has reeled in a $75 mil­lion Se­ries D, and its CEO Matthew Ros is walk­ing off the course for “oth­er pro­fes­sion­al pur­suits,” the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times